Últimas noticias sobre Myriad Genetics (NASDAQ:MYGN) Bolsa

Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics Inc

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.
The Dow traded up 0.67% to 42,043.38 while the NASDAQ surged 0.75% to 18,230.53. The S&amp;P 500 also rose, gaining, 0.47% to 5,732.21.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.3% on Friday.
In trading on Friday, utilities shares fell by 2.1%.
Top Headline
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell around 2% on Friday after the company reported results for the fourth quarter.
The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share.
<h3 class="wp-block-heading">Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 53% to $5.34 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.42 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.23 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 71% to $1.51 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.30. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 37% to $1.2250. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $69.79 while gold traded down 0.1% at $2,745.60.
Silver traded down 0.7% to $32.555 on Friday, while copper rose 0.3% to $4.3520.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.09%, Germany's DAX gained 0.93% and France's CAC 40 gained 0.80%. Spain's IBEX 35 Index surged 1.46%, while London's FTSE 100 rose 0.83%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
<li>The total number of active U.S. oil rigs fell by one to 479 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

AAPL

CDXC

EPIX

LXRX

MYGN

PRLB

TILE

Crude Oil Moves Higher; Apple Shares Slide After Q4 Results

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

ATHA

BFRI

ALPS ETF Trusthen & Steers Global Realty Majors ETF

PDEX

PLSE

TOVX

XAIR

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday.
The Dow traded up 1.18% to 42,254.81 while the NASDAQ surged 1.31% to 18,332.35. The S&amp;P 500 also rose, gaining, 0.95% to 5,759.63.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.9% on Friday.
In trading on Friday, utilities shares fell by 1.1%.
Top Headline
Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares surged 7% on Friday after the copany posted stronger-than-expected results for the third quarter.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 55% to $5.41 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 31% to $36.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.15 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 70% to $1.58 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.24. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 36% to $1.2550. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $70.04 while gold traded up 0.2% at $2,753.70.
Silver traded down 0.1% to $32.755 on Friday, while copper rose 0.5% to $4.3635.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.25%, Germany's DAX gained 1.10% and France's CAC 40 gained 1.05%. Spain's IBEX 35 Index surged 1.42%, while London's FTSE 100 rose 1.06%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

AMZN

Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results

Guidance

Myriad Genetics Reaffirms Previously Issued FY24 Revenue And Adj. Guidance Previously Provided On August 6 During Its Q2 Earnings Call

In addition, based partially on the Company&#39;s preliminary results for the third quarter of 2024, the Company is reaffirming its previously issued revenue and non-GAAP financial guidance for the full-year 2024 previously provided on August 6, 2024 during its second quarter 2024 earnings call. This guidance included full year 2024 revenue expectations of between $835 million and $845 million.

Myriad Genetics Discloses Certain Preliminary Financial Data For Q3, Expects Revenue Of $210M - $212M (Est $209.397M), Despite Divestiture Of EndoPredict Business In Europe - Filing

Myriad Genetics Reveals Series Of Ongoing Research Collaborations To Study Use Of Molecular Residual Disease Testing In Breast Cancer Using Precise MRD Test

<a href="https://www.globenewswire.com/Tracker?data=FaeImwHFSrdIr3Whx5NVoW1Uj1rIQl4XG_FGofXhlX3u3Hg9zWoRBS2wyn2_cPl9zqQKwcmHujJ1-24smichVLBsgCbeDbvSbf3jhCAsrf4nCgsEQb-2zL4hbX1eOBuCM4tBmkCozNBxfp5RNdWvdXy2-oKG0q2mSG-Nn8TbMK-bF_Z_rriuwZe7iU9aGiPd8WhyZLAhjSx7GWYbp5qmcbVbLe6xxWy8VMFfi7CY1Ls=">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100&#x2122;&nbsp;sequencing platform and its ppmSeq&#x2122;&nbsp;technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. &nbsp;
The low-cost and low-error sequencing achievable on the UG 100 may benefit several of Myriad's emerging products that require large amounts of high-fidelity sequencing data. The Myriad Precise Molecular Residual Disease (MRD) test performs whole-genome sequencing on two samples from cancer patients—one from a tumor and one from normal tissue—to comprehensively identify tumor-specific variants for subsequent tracking in a personalized panel. With Ultima's support, Myriad will explore the potential for the Precise MRD test to improve in both performance and cost with ppmSeq on the UG 100. In the reproductive-health space, Myriad is expected to launch its FirstGene Multiple Prenatal Screen, which will run the content of multiple prenatal screens via a single sequencing workflow. FirstGene also requires deep and accurate sequencing that the UG 100 platform may be well suited to affordably provide.

Biotech

General

Myriad Genetics And Ultima Genomics To Explore The UG 100 Sequencing Platform To Advance Clinical Test Offerings In Oncology And Reproductive Genomics

Myriad Genetics Says USPTO Issued Third Patent For Molecular Residual Disease With Early Priority Date

7 analysts have shared their evaluations of Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $30.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 17.65% increase, the current average has risen from the previous average price target of $25.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747212_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Myriad Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$34.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Myriad Genetics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
<h2>Get to Know Myriad Genetics Better</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Financial Insights: Myriad Genetics</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's net margin is impressive, surpassing industry averages. With a net margin of -17.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.89%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.34%, the company showcases effective utilization of assets.
Debt Management: Myriad Genetics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.19, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Myriad Genetics's Future

Morgan Stanley analyst Tejas Savant initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight rating and announces Price Target of $32.

Price Target

Initiation

Morgan Stanley Initiates Coverage On Myriad Genetics with Equal-Weight Rating, Announces Price Target of $32

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
Shares of G-III Apparel Group, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) rose sharply during Thursday's session after the company reported better-than-expected second-quarter adjusted EPS results and issued its FY25 guidance above estimates.
G-III Apparel Group reported second-quarter adjusted earnings per share of 52 cents, beating the analyst consensus of 27 cents. Quarterly revenues of $644.75 million (down 2%) missed the street view of $649.44 million.
G-III Apparel Group shares surged 23.6% to $30.95 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares jumped 68.1% to $5.45 after the company entered agreements for a $160 million private placement financing priced at market, from a group of institutional and accredited investors including NVIDIA and Related Companies.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) gained 14.9% to $21.15.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) climbed 13.5% to $8.81.</li>
<li>Uniti Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) rose 13.3% to $5.32.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) climbed 13% to $5.56 after the company reported better-than-expected second-quarter adjusted EPS results and issued FY25 revenue guidance above estimates. Also, Needham upgraded the stock from Hold to Buy and announced an $8 price target.</li>
<li>Perpetua Resources Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) rose 11.8% to $9.05 after the company announced the U.S. forest service has completed the final environmental impact statement and issued a draft record of decision authorizing the Stibnite gold project.</li>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) gained 11.7% to $15.28 following a report suggesting Elis SA made an offer to buy the company.</li>
<li>WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) climbed 10.7% to $18.63.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 10.4% to $4.6850 after the company reported second-quarter financial results and issued better-than-expected third-quarter outlook..</li>
<li>Shoe Carnival, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) rose 10% to $41.32 after the company reported better-than-expected second-quarter revenue results. Also, the company raised its FY24 guidance.</li>
<li>Primo Water Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NASDAQ">PRMW</a>) gained 9.4% to $23.92.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) gained 8.5% to $43.79. Craig-Hallum analyst Alexander Nowak upgraded QuidelOrtho from Hold to Buy and raised the price target from $40 to $57.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 8.3% to $1.3095.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) gained 7.9% to $27.36.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 7.8% to $26.83. Zeta Global priced $204.9 million public offering of 13.2 million class A common shares at $23.50 per share.</li>
<li>Sotera Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) gained 7.7% to $16.59. The company announced a secondary offering of 25 million shares.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) rose 6.2% to $67.52. Dollar Tree, on Wednesday, reported worse-than-expected second-quarter 2024 earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40728954/how-to-earn-500-a-month-from-smith-wesson-brands-stock-ahead-of-q1-earnings-report">How To Earn $500 A Month From Smith &amp; Wesson Brands Stock Ahead Of Q1 Earnings Report</a></li>
</ul>

Intraday Update

APLD

DLTR

GIII

Larimar Therapeutics, Inc. - Common Stock

LRMR

PPTA

PRMW

PSNY

QDEL

SATS

SCVL

UNIT

VSTS

YEXT

ZETA

G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday

WIIM

Myriad Genetics shares are trading lower after the company announced that it discontinued the second part of its study due to the disparities between the GeneSight Group and control group.

Myriad Genetics Said Due To Significant Disparities Between GeneSight Group And Control Group, Myriad Concluded That The Control Group Was Not Viable, Leading To The Discontinuation Of The Second Part Of The Study

Wells Fargo analyst Brandon Couillard initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Overweight rating and announces Price Target of $35.

Wells Fargo Initiates Coverage On Myriad Genetics with Overweight Rating, Announces Price Target of $35

Alcon (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alc#NYSE">ALC</a>) has been gaining from a strong pipeline and its focus on research and innovation. Market share gains also aid growth. The stock currently carries a Zacks Rank #2 (Buy).
In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon currently leads the market with more than 60% share globally and over 80% share in the United States. In Surgical, the company maintains a strong market share in PCIOLs, driven by strong demand for products like PanOptix and Vivity despite new market entrants. Vivity&#39;s non-diffractive properties, ease of use and consistency of surgical outcomes make it particularly appealing.
Within Surgical, Alcon commercially launched SMARTCataract in the United States. This is expected to broaden the scope of the company in the growing surgical ophthalmology space. The company currently sees meaningful share gains driven by its new toric product launches, including Precision1, Total30 and Dailies Total1.
The company will offer a cataract-only system called UNITY CS, which will be available in 2026. Importantly, UNITY brings with it new and innovative consumables that drive incremental benefits for the surgeon. The launch of these instruments will help the company secure the next decade of the company&#39;s consumables business, which is a large, recurring and profitable revenue stream.
In ocular health, the company is also expanding business with the integration of Rocklatan and Rhopressa and concluded Phase 3 trials for AR-15512, the dry-eye pharmaceutical candidate. In addition, the company is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products. The company looks forward to the growing demand for its multi-dose preservative-free formulations, which are helping expand the U.S. preservative-free category.
Alcon&#39;s Surgical business continues to gain from a diverse portfolio and incremental innovation. In terms of the latest developments within Implantables, Alcon&#39;s technology continues to lead the market. Globally, one out of every three IOLs implanted is done with an Alcon lens. In premium lenses, the statistic is even more impressive, with one out of two ATIOLs being an Alcon product. The company&#39;s flagship lenses, Vivity and PanOptix, continue to lead the category in the United States and around the world. Additionally, it continues to expand in areas where it has significant opportunities to grow share, such as China.
<div class="chart_embed">
<h3>Alcon Price</h3>
<img alt="Alcon Price" src="https://staticx-tuner.zacks.com/images/charts/62/1724161553.png" style="height:251px; width:538px" title="" />
Alcon price | Alcon Quote
Within the Surgical franchise, revenues were up 6% year over year in the first quarter, mainly driven by advanced technology intraocular lenses, including Vivity, PanOptix and monofocal torics in international markets.
</div>
Within Vision Care, Alcon is registering solid growth, banking on strong sales of its contact lenses and ocular health products. In contact lenses, the company is successfully executing its strategy of investing in fast-growing market segments where it has significant share opportunities. As a result, Alcon is outpacing market growth in every category where it has launched new products.
In contact lenses, Alcon with its strategic investments, has secured its position as one of the fastest-growing companies. It is witnessing strong interest in its specialty lenses, including multifocal and toric.
On the flip side, Alcon is experiencing inflationary pressure in electronic components, freight, labor, resins and plastics, impacting the company&#39;s margins. The company is also encountering supply chain challenges in certain components, including microchips, resins and plastics, metals and filters. The company expects these inflationary pressures and supply chain challenges to continue in 2024. The cost of net sales in the first quarter was up 2.9% year over year. Our model estimates a 5.4% increase in the metric for full-year 2024.
Meanwhile, the ophthalmology industry is highly competitive. In the surgical business, Alcon competes with large manufacturers with multiple business lines as well as small manufacturers that offer a limited selection of specialized products. The company also&nbsp;faces competition&nbsp;from&nbsp;providers&nbsp;of&nbsp;alternative&nbsp;medical&nbsp;therapies,&nbsp;such&nbsp;as&nbsp;pharmaceutical&nbsp;companies that have&nbsp; the potential to disrupt core elements of its business.
In vision care business, the market for contact lenses is intensely competitive and is characterized by declining sales volumes for older and reusable product lines and growing demand for daily lenses and advanced materials lenses. Increased product entries from contact lens manufacturers in Asia also pose a massive threat.
<h3>Other Key Picks</h3>
Some other top-ranked stocks in the broader medical space are Masimo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>), Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>) and Myriad Genetics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>). While Masimo sports a Zacks Rank #1 (Strong Buy) at present, Boston Scientific and Myriad Genetics carry a Zacks Rank #2 each.
Masimo shares have risen 10.8% in the past year. Estimates for the company&#39;s earnings have increased from $3.63 to $3.83 for 2024 and from $3.97 to $4.20 for 2025 in the past 30 days.
MASI&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 14.6%. In the last reported quarter, it posted an earnings surprise of 11.7%.
Estimates for Boston Scientific&#39;s 2024 earnings per share have moved up to $2.40 from $2.32 in the past 30 days. Shares of the company have rallied 56% in the past year compared with the industry&#39;s rise of 11.1%.
BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for Myriad Genetics&#39; 2024 earnings have moved up to 5 cents from 3 cents per share in the past 30 days. Shares of the company have improved 59.3% in the past year against the industry&#39;s 3.1% fall.
MYGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 213.4%. In the last reported quarter, it delivered an earnings surprise of a staggering 600%.
<a href="https://www.zacks.com/stock/news/2324522/alcon-s-alc-market-share-gains-new-launches-aid-growth?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2324522">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Mid Cap

MASI

Alcon's Market Share Gains, New Launches Aid Growth

Quest Diagnostics Inc.&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) sustained growth momentum within the legacy base business is poised to help it grow in the upcoming quarters. Strong progress in the company&#39;s highly specialized Advanced Diagnostics offerings is encouraging. Additionally, the cost discipline program, Invigorate, is boosting productivity through automation and AI. However, a debt-laden balance sheet and challenges from fierce competition are concerning for DGX&#39;s operations.
In the past year, this Zacks Rank #2 (Buy) stock has rallied 11.3% compared with the industry&#39;s 13.6% growth and the 19.3% rise of the S&amp;P 500 composite.
The renowned provider of diagnostic information services has a market capitalization of $16.62 billion. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.31%.
Let&#39;s delve deeper.
<h3>Tailwinds</h3>
Growth Momentum in the Base Business Continues: Quest Diagnostics has been experiencing robust volume growth in its core business (excluding Covid Testing), banking on the growth of new physician and hospital customers, a more favorable test mix with increased use of advanced diagnostics, continued strength in healthcare utilization as well as the ongoing return to care. The latest second quarter of 2024 also marked another strong base business growth for Physician Lab Services, driven by overall market growth and share gains on new customer wins.
Added to this, the company delivered strong volume and revenue growth from its Medicare Advantage plans. PLS and hospital reference testing have been outpacing both historical trends and market growth projections. Additionally, DGX is making headway with several promising opportunities within its robust M&amp;A pipeline, such as the recently closed acquisition of PathAI Diagnostics. Further, Quest Diagnostics&#39; strong consumer focus is driving growth in consumer-initiated testing and expanded access to basic health care.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/f8/74120.jpg?v=1390132318" /> 
Image Source: Zacks Investment Research
Strong Potential of Advanced Diagnostics:&nbsp;Quest Diagnostics&#39; Advanced Diagnostics offerings have generated robust growth in recent quarters. A key driver in Brain Health growth is the company&#39;s Alzheimer&#39;s disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring. The acquisition of the cancer testing company, Haystack Oncology, has strategically placed DGX in the higher-growth clinical area of ctDNA (Circulating tumor DNA) solid-tumor MRD (minimal residual disease) testing.
Alongside this, the company has been expanding the pool of evidence on the clinical and economic value of ctDNA blood testing in cancer care. Furthermore, Quest Diagnostics&#39; STEP500 somatic tumor sequencing service is gaining interest from large cancer centers.
A Strategic Imperative to Drive Operational Excellence:&nbsp;As part of its broader strategy to drive operational improvements across the business, Quest Diagnostics strategically deploys automation and AI to improve quality, service, efficiency and the workforce experience. The company&#39;s multi-year cost excellence program, Invigorate, has consistently delivered 3% annual cost savings and productivity enhancements, acting as a shield against inflationary pressures such as rising labor and benefit costs and reimbursement challenges. In the second quarter, it enhanced the use of automation and AI to improve productivity, as well as service levels and quality.
<h3>Headwinds</h3>
Escalating Debt Level: At the end of the second quarter of 2024, the company had long-term debt of $3.82 billion on the balance sheet, while the cash and cash equivalent balance was only $271 million. The current portion of the debt stood much higher at $606 million, raising concerns about its liquidity position.
Competitive Landscape: Quest Diagnostics faces intense competition, primarily from LabCorp, other commercial laboratories and hospitals. While pricing is an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service, including an accurate and rapid turnaround of testing results. As a result, Quest Diagnostics and other commercial labs compete mainly on the quality of service.&nbsp;&nbsp;&nbsp;&nbsp;
<h3>Estimate Trend</h3>
The Zacks Consensus Estimate for Quest Diagnostics&#39; 2024 earnings per share has moved up to $8.88 from $8.79 in the past 30 days.
The consensus estimate for the company&#39;s 2024 revenues is pegged at $9.52 billion. This suggests a 2.9% rise from the year-ago reported number.
<h3>Other Key Picks</h3>
Some other top-ranked stocks in the broader medical space are TransMedix Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>) and Myriad Genetics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>).
TransMedix Group&#39;s earnings are expected to surge 242.9% in 2024. The company&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Its shares have soared 160.4% compared with the industry&#39;s 5.2% rise in the past year.
TMDX sports a Zacks Rank #1 (Strong Buy) at present.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 17.1% compared with the industry&#39;s 15.5%. Shares of the company have rallied 48% compared with the industry&#39;s 5.2% rise over the past year.
BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Myriad Genetics, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 51.3% compared with the industry&#39;s 21.4%. Shares of the company have jumped 56.9% compared with the industry&#39;s 5.2% growth over the past year.
MYGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 213.4%.
<a href="https://www.zacks.com/stock/news/2321155/should-quest-diagnostics-dgx-be-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2321155">To read this article on Zacks.com click here.</a>

Health Care

TMDX

Should Quest Diagnostics be in Your Portfolio Now?

Scotiabank analyst Sung Ji Nam maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Sector Outperform and raises the price target from $29 to $34.

Scotiabank Maintains Sector Outperform on Myriad Genetics, Raises Price Target to $34

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of $25.8, a high estimate of $30.00, and a low estimate of $20.00. This current average has increased by 5.31% from the previous average price target of $24.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1723554061_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Myriad Genetics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
<h2>Delving into Myriad Genetics's Background</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Financial Milestones: Myriad Genetics's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Myriad Genetics's net margin excels beyond industry benchmarks, reaching -17.35%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.89%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: Myriad Genetics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and raises the price target from $28 to $30.

Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $30

Myriad Genetics, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>) reported adjusted earnings of 5 cents per share in the second quarter of 2024 compared to the Zacks Consensus Estimate of a loss of 1 cent per share. The reported figure also compares to a loss of 8 cents per share in the year-ago quarter.
The quarter&#39;s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization, among others.
<h3>Revenues</h3>
Total revenues rose 15.3% year over year to $211.5 million in the quarter under review. The figure topped the Zacks Consensus Estimate by 2.9%. Testing volumes increased 9% year over year.
Quarter in Detail
Hereditary Cancer testing revenues rose 19% year over year to $91.5 million.
Pharmacogenomics testing revenues were $43 million, up 22% year over year.
<div class="chart_embed">
<h3>Myriad Genetics, Inc. Price, Consensus and EPS Surprise</h3>
<img alt="Myriad Genetics, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/42/1723113961.png" style="height:265px; width:580px" title="" />
Myriad Genetics, Inc. price-consensus-eps-surprise-chart | Myriad Genetics, Inc. Quote
Tumor Profiling testing revenues fell 9% year over year to $32.6 million.
</div>
Prenatal testing revenues came in at $44.4 million, up 25% year over year.
<h3>Margin Trends</h3>
The gross margin in the quarter under review expanded 105 basis points (bps) to 69.6%.
Research and development expenses rose 27.8% year over year to $27.1 million. SG&amp;A expenses increased 3% to $144.9 million in the reported quarter.
The adjusted operating loss was $24.9 million compared with $36.2 million in the year-ago quarter.
<h3>Financial Position</h3>
Myriad Genetics exited the second quarter of 2024 with cash and cash equivalents of $92.4 million compared with $96.9 million at the end of the first quarter.
Long-term debt was $38.8 million compared with $38.7 million at the end of the first quarter.
The cumulative net cash used in operating activities at the end of the reported quarter was $16 million compared with the $34.1 million cash outflow in the year-ago period.
<h3>2024 Guidance</h3>
Myriad Genetics provided an updated 2024 outlook.
The company expects its revenues in the range of $835-$845 million (earlier $820-$840 million), suggesting 11-12% (previously 9%-11%) growth over 2023 revenues. The Zacks Consensus Estimate for the same is pegged at $834.2 million.
Adjusted earnings per share are expected in the range of 8 cents-12 cents (previously flat to 5 cents). The Zacks Consensus Estimate for the same is pegged at 3 cents.
Meanwhile, the company also raised its long-term revenue growth target to 12%.
<h3>Our Take</h3>
Myriad Genetics delivered better-than-expected earnings and revenues in the second quarter of 2024. The performance across the portfolio was strong, highlighted by the market share gains in prenatal testing. Average revenue per test improved across the product portfolio, benefiting from expanded coverage and ongoing efforts in revenue cycle management.
In addition, the company continues to improve access and ease of use for its customers by accelerating electronic medical record integrations for new customers and making meaningful progress in its Labs of the Future initiative.
Notable highlights in the quarter include a collaboration with GSK aimed at improving access to homologous recombination deficiency diagnostic testing for high-grade serous ovarian cancer patients, the launch of the Universal Plus Panel for Foresight Carrier Screen and an agreement with QIAGEN to develop a globally distributable HRD test for global research and companion diagnostics applications. The revised guidance for the full year and the long-term revenue growth rate instill optimism.
Meanwhile, the decline in tumor profiling revenues reflected the ongoing challenges in the biopharma environment, a slow ramp of biopharma contracts executed in 2023 and constraints in the international business.
<h3>Zacks Rank and Key Picks</h3>
Myriad Genetics currently carries Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), Abbott Laboratories, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) and Quest Diagnostics (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>).
Intuitive Surgical reported a third-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has an estimated long-term earnings growth rate of 16.1% in 2024 compared with the industry&#39;s 14.1%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 8.97%.
Abbott, carrying a Zacks Rank #2 (Buy), reported third-quarter 2024 earnings of $1.14, which surpassed the Zacks Consensus Estimate by 3.6%. Revenues of $10.38 billion topped the Zacks Consensus Estimate by 0.3%.&nbsp;
ABT has an estimated earnings growth rate of 10.1% for 2025 compared&nbsp; &nbsp; with the S&amp;P 500&#39;s 9.3%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 2.34%.
Quest Diagnostics, carrying a Zacks Rank #2, reported a third-quarter adjusted EPS of $2.35, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion exceeded the Zacks Consensus Estimate by 0.5%.
DGX&#39;s historical five-year earnings growth rate of 7.4% compared favorably with the industry&#39;s 4.2%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 3.31%.
<a href="https://www.zacks.com/stock/news/2318906/myriad-genetics-mygn-q2-earnings-surpass-24-outlook-raised?cid=CS-BENZ-FT-analyst_blog|earnings_article-2318906">To read this article on Zacks.com click here.</a>

ISRG

Myriad Genetics Q2 Earnings Surpass, '24 Outlook Raised

In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Sell rating on Myriad Genetics (MYGN – Research Report), with a price...

Myriad Genetics: Assessing Sustainability of Revenue Growth Amid Market Challenges

Wells Fargo analyst Brandon Couillard maintained a Buy rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $35.00. B...

Myriad Genetics: A Buy Rating Amid Reaffirmed Strategy and Growth Potential

Leerink Partners analyst Puneet Souda has maintained their bullish stance on MYGN stock, giving a Buy rating yesterday. Puneet Souda's rating is ba...

Myriad Genetics: Strategic Growth and Raised Price Target Reinforce Outperform Rating

Scotiabank analyst Sung Ji Nam reiterated a Buy rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $34.00. The comp...

Scotiabank Keeps Their Buy Rating on Myriad Genetics (MYGN)

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price tar...

Steady Growth and Market Stability Justify Hold Rating for Myriad Genetics

Myriad Genetics enters into strategic partnership with jscreen

Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on...

Piper says Myriad appears to be trading down on GeneSight coverage change

Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm blames on an announcement f...

Myriad weakness due to UnitedHealth coverage update, says Stephens

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad's (MYGN) GeneSight, effectiv...

UnitedHealth update 'not the end' for Myriad's GeneSight, says Raymond James

Press Releases

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Myriad Genetics to Host Investor Event on October 9, 2024

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Legal

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Comments

Myriad Genetics

Noticias

Últimas noticias sobre Myriad Genetics (NASDAQ:MYGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL